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Abstract
Objectives—To validate the preliminary criteria of global flare for childhood-onset SLE (cSLE).
Methods—Pediatricians experienced in cSLE care (n=268) rated unique patient profiles (PP); 
results of standard cSLE laboratory testing and information about the cSLE flare descriptors were 
presented: global assessment of patient well-being, physician global assessment of disease activity 
(MD-global), disease activity index score, protein/creatinine ratio (PCR), and ESR. Using rater 
interpretation of the course of cSLE (baseline vs. follow-up as the gold standard), performance 
[sensitivity, specificity, area under the receiver operating characteristic curve (AUC)] of the 
preliminary flare criteria (Arthritis Care & Research, 2011) was tested. An international consensus 
conference was held to rank the preliminary flare criteria as per the ACR-recommendations and 
delineate threshold scores for minor, moderate and major flares.
Results—The accuracy of the two highest ranked candidate criteria which consider absolute 
changes (∆) of the SLEDAI or BILAG (numeric scoring: A=12; B=8; C=1; D/E=0), MD-global, 
PCR, and ESR were confirmed (both AUC > 0.93). For the SLEDAI-based criteria [0.5x 
∆SLEDAI + 0.45x ∆PCR + 0.5x ∆MD-global + 0.02x ∆ESR] flare scores ≥6.4/3.0/0.6 constituted 
major/moderate/minor flares. For the BILAG-based algorithm [0.4x ∆BILAG + 0.65x ∆PCR+0.5x 
∆MD-global + 0.02x ∆ESR] flare scores ≥7.4/3.7/2.2 delineated major/moderator/minor flares. 
These threshold values (SLEDAI, BILAG) were all >82% sensitive and specific for capturing flare 
severity.
Conclusions—Provisional criteria for global flares in cSLE are available to identify patients 
who experienced a flare. These criteria also allow for discrimination of the severity of cSLE 
exacerbations.
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INTRODUCTION
Systemic lupus erythematosus is a complex, chronic multi-system autoimmune 
inflammatory disease, with up to 20% of patients diagnosed during childhood (cSLE) (1, 2). 
When disease commences early in life rather than during adulthood, it has a less favorable 
prognosis, particularly due to multi-organ and kidney involvement (3, 4). The course of 
cSLE is characterized by episodes of disease flares; followed by periods of improvement, 
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generally due to more intensive drug therapy. There is international consensus that a flare of 
cSLE is “a measurable worsening of disease activity in at least one organ system, involving 
new or worse signs of disease that may be accompanied by new or worse SLE symptoms; 
depending on the severity of the flare, more intensive therapy may be required” (5). Further, 
using consensus formation techniques, agreement has been achieved regarding preliminary 
criteria of global flare of cSLE based on changes of the erythrocyte sedimentation rate 
(ESR), the protein/creatinine ratio (PCR), physician global assessment of cSLE activity 
(MD-global), and the score of the Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) (6, 7) or the British Isles Lupus Activity Group index (BILAG) (8). Moreover, 
there is consensus around the need to discriminate flares as per their severity: mild/minor, 
moderate, and major/severe flares (5). However, there are no generally accepted criteria or 
algorithms to determine how to measure the severity of cSLE flares, nor have the 
preliminary cSLE flare criteria been validated in an independent dataset. Thus, the 
objectives of this phase of the project were to validate the preliminary criteria of global flare 
of cSLE and to apply consensus formation methodology to define flare threshold levels for 
minor, moderate and major flares. These criteria were created to define cSLE flares and their 
severity for use in clinical trials.
PATIENTS AND METHODS
The overall approach to this project was based on the methodological framework 
successfully employed in pediatric rheumatology criteria measures in the past (9–11), 
aligned with recommendations of the ACR Criteria Subcommittee and the Quality of Care 
Committee (QOC) (12). The initial results of the consensus process resulting in preliminary 
cSLE flare criteria have been described elsewhere (5, 13). Briefly, previous research 
demonstrated that the scores of a disease activity measure alone are inadequate for 
identifying flares (5). International agreement was reached regarding preliminary criteria to 
measure global flares of cSLE. Pediatric rheumatologists participated in Delphi surveys that 
yielded consensus around a common definition of cSLE global flares, and the delineation of 
cSLE flare descriptors. This was followed by exploration of candidate flare criteria (5) and 
the identification of preferred algorithms of global cSLE flares (14). Notably, data and 
analyses all suggested that uniform percentage changes of the cSLE flare descriptors are 
insufficient to capture cSLE flares with high sensitivity. Further, inclusion of the MD-global 
assessment of cSLE activity in highly accurate cSLE candidate flare algorithms proved 
necessary (5, 15). During the first Consensus Conference the top-performing candidate flare 
algorithms, derived either from multinomial logistic regression modeling or classification 
tree analysis (CART) were established.
We now present the phase of the project aimed at validating the preferred preliminary flare 
algorithms (14) via testing in an independent validation data set (Figure 1). These 
encompassed Patient Profiles PP ratings that were requested from 503 pediatric 
rheumatologists from Australia, Africa, Asia, Europe and the Americas who were members 
of at least one of the following organizations: Pediatric Rheumatology Collaborative Study 
Group, Childhood Arthritis Rheumatology Research Alliance, Pediatric Rheumatology 
European Society Juvenile Lupus Working Group, and Pan-American League of Arthritis & 
Rheumatology [Step 1].
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The interpretation of the flare or ‘true’ disease course of a given PP was determined using 
two approaches, which resulted in two distinct datasets for the subsequent validation 
exercises [Step 2]. Using the PP ratings, the preliminary criteria for cSLE global flares were 
tested for their ability to discriminate patients who experienced different levels of flares 
(minor, moderate, major) [Step 3]. Subsequently, during a Consensus Conference, the 
validity of the criteria was critically reviewed, taking into consideration information from 
the medical literature, statistical performance, reliability, feasibility, and face validity as per 
the ACR guidance document and the OMERACT filter (16) [Step 4].
Preliminary cSLE Flare Algorithms
We considered the top four preliminary flare algorithms (identified in the first Consensus 
Conference) based on feasibility, truthfulness and discrimination (17). Two of the four 
preliminary cSLE flare algorithms [SLEDAI-based criteria: 0.5x ∆SLEDAI + 0.45x ∆PCR 
+ 0.5x ∆MD-global + 0.02x ∆ESR; BILAG-based criteria: 0.4x ∆BILAG + 0.65x ∆PCR
+0.5x ∆MD-global + 0.02x ∆ESR] were derived by multinomial logistic regression that 
considered several of the cSLE flare descriptors, and yield “flare scores” (or log odds of 
flare), with higher score representing a higher likelihood of a flare to have occurred. The 
other two of the top preliminary flare criteria were derived from CART [SLEDAI-CART: 
Score=4 if 3 ≤ SLEDAI; Score=3 if 0.7 ≤ PCR and 3 > SLEDAI; Score=2 if 2 ≤ MD and 0.7 
> PCR and 3 > SLEDAI; and Score=1 Otherwise; BILAG-CART: Score=4 if 2 ≤ BILAG; 
Score=3 if 0.7 ≤ PCR and 2 > BILAG; Score=2 if 2 ≤ MD and 0.7 > PCR and 2 > BILAG; 
Score=1 Otherwise]. Similar to algorithms derived by multinomial logistic regression, 
CART-based criteria yield ‘CART-scores’ that can be used to decide on the presence of a 
flare, including its severity (18).
Step A: Patient Profiles & Ratings of Disease Course of a Patient Profile
Two of the authors (MH, HIB) conducted a pilot study to test the format of the PP. Built on 
this pilot study, we generated over 2,996 unique PPs, using prospectively collected data of 
cSLE patients from the CCHMC Lupus Registry (19), the PRINTO Lupus Cohort (20), the 
United Kingdom Juvenile-onset SLE Cohort Study (21), and the APPLE trial (22). Missing 
observations in the datasets were imputed using multiple imputation methods and 
expectation–maximization algorithms in computation (23–25).
Each PP provided data about a patient at the time of a baseline visit and a follow-up visit. 
For each PP visit, the cSLE flare descriptors were provided (5): [1] MD-global, measured on 
a visual analog scale (VAS) (0 = inactive disease; 10 = very active disease); [2] parent 
assessment of patient overall well-being, measured on a VAS with a range from 0 to 10 (0 = 
very poor; 10 = very well); [3] proteinuria, measured by timed urine collection or spot PCR; 
[4] ESR; [5] levels of complement C3 and C4; [6] item and summary scores of the SLEDAI, 
version 2k (7), or the domain and summary scores of the BILAG using the following 
numeric conversion: A=12; B=8; C=1; D/E=0 (8). Information on complete blood counts 
and differential, serum chemistry, urinalysis and anti-dsDNA antibodies were also provided. 
Details on PP formats are provided in Appendix 1.
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Disease Course—PP raters were randomly assigned to assess the disease course of a 
maximum of 51 PP. Response options offered were: major flare; moderate flare; minor flare; 
unchanged; improved; or “I do not have enough information to make this assessment”. A 
global flare was considered as “present” whenever the disease course was rated as minor, 
moderate, or major flare.
Step B: Adjudication of Disease Course of the PP
A randomization scheme was pre-planned to ensure that each PP was sent to about 13 raters, 
with the ratio of American and international raters matching that of the PP raters’ pool 
(about 1:1). PP with fewer than 4 ratings were regarded as “invalid” or “unqualified” and 
excluded from further consideration. Only “qualified” PP with successful adjudication were 
considered in Step 3.
Adjudication of the (true) disease course—Given that PP raters may not necessarily 
agree on the disease course, the “true” overall course of cSLE for a given PP was 
adjudicated using two approaches; (a) 67%-Rule: at least 2/3 of the raters agreed on a given 
disease course, (b) Majority-Rule: the majority of the raters of a PP agreed on a given 
disease course. Other Rules (50%-Rule and 75%-Rule) were also explored and results were 
similar to the Majority-Rule and the 67%-Rule, respectively; hence they are not presented 
herein.
Step C: Assessment of Performance
Statistical analysis in preparation of the testing of preliminary flare criteria—
Considering the intended widespread use of the cSLE flare criteria (14), we tested whether 
there were systematic differences in the ratings provided by raters (a) from different 
geographic regions, or (b) with varying professional experience as measured by the duration 
of medical practice. Agreement among raters was assessed using intra-class correlation 
coefficients (ICC) and/or Kappa (κ) statistics. An ICC or a κ value can be interpreted as 
follows: poor agreement: ICC or κ< 0.4; fair to good agreement: ICC or κ≥ 0.4– 0.75; 
substantial to excellent agreement: ICC or κ> 0.75 (26).
Performance & Accuracy—Each of the four flare algorithms (SLEDAI-based criteria, 
BILAG-based criteria, SLEDAI-CART, BILAG-CART) was assessed for diagnostic 
accuracy using receiver’s operating characteristic (ROC) curve analysis. Specifically, the 
area under the ROC curve (AUC) was calculated, and the diagnostic accuracy was 
considered outstanding, excellent, good, fair, and poor if the AUC was in the range of 0.9–
1.0, 0.81–0.90, 0.71–0.80, 0.61–0.70, and < 0.60, respectively (18, 27). Different from flare 
criteria derived from multinomial regression models (SLEDAI-based criteria, BILAG-based 
criteria), CART-based flare algorithms (SLEDAI-CART and BILAG-CART) result in a 
single discrete value for sensitivity and specificity, respectively. Considering all possible 
flare scores, the overall diagnostic accuracy of an algorithm can be estimated.
Threshold score candidates for algorithms derived by multinomial logistic 
analysis—In the absence of strong guidance from the ACR, we used two statistical 
methods to define potential threshold scores: (a) in an earlier phase of the project, consensus 
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had been achieved that “flare score threshold” for a given algorithm should reflect the 
highest conditional AUC among all candidate thresholds on a ROC curve. Hence, these flare 
score thresholds represent the point on the ROC curves with the highest precision of 
correctly classifying the severity of a cSLE flare. (b) We also explored a distribution-
weighted approach in which the flare score threshold was calculated based upon the average 
of means of scores in two neighboring flare states weighted by the standard deviations of the 
scores. The performance of the candidate thresholds from both statistical analyses (a, b) was 
calculated and average accuracies for the correct identification of minor, moderate and major 
flares for the SLEDAI-based and BILAG-based algorithms.
Step D: Ranking of Candidate Flare Criteria &Thresholds Score
To support decision making, Consensus Conference participants reviewed a syllabus that 
provided the results of the preceding Delphi surveys, relevant published medical literature 
and the results of the statistical analyses prior to the Consensus Conference (see Step 3). 
Participants in the Consensus Conference were 13 experienced pediatric rheumatologists and 
nephrologists from South America, North America, Asia, and Europe with substantial 
clinical and research experience in cSLE (HIB, MWB, SPA, SA, CAS, FF,BG, SEW, DML, 
AR, RK, TA, and MKG). A priori, the consensus level at the consensus conference was set 
at 75%, i.e. comparable or even somewhat higher than that chosen for similar studies in the 
past (15–19). Using nominal group technique guided by an experienced moderator (BMF), 
the expert panel assessed each of the four top candidate flare algorithms (14) and potential 
flare score thresholds according to [1] feasibility, i.e. practicability: can the items be 
measured easily?; [2] reliability, i.e. reproducibility: can the items be measured precisely?; 
[3] redundancy: are there two or more items included in the candidate criteria measuring the 
same aspect of the disease?); [4] face validity, i.e. credibility: are the criteria sensible?; [5] 
content validity, i.e. comprehensiveness: do the criteria sample all of the domains of the 
disease?; [6] criterion validity: based on AUC, do the criteria accurately approximate the 
“gold standard”, i.e. the adjudicated disease course as per 67%-Rule or Majority-Rule?; [7] 
sensitivity and specificity: do the criteria effectively identify patients with cSLE flares and 
distinguish them from patients who do not have a flare of their cSLE?; and [8] discriminant 
validity: do the criteria detect the smallest clinically important change? (i.e. discriminate 
patients with one of the following disease courses: minor flare, moderate flare, major flare, 
no flare). Based on the above considerations, the Consensus Conference experts were asked 
to rank the candidate flare criteria from 1 (lowest) to 4 (highest criterion).
The survey source data were batch-processed, and open source online survey software, 
Limesurvey, was used for response management and as a presentation layer (see http://
www.limesurvey.org/).
All analyses were done using SAS 9.4 (SAS, Cary, NC) software and SYSTAT 12 (Systat 
Software, Inc, Chicago, IL) software. P-values < 0.05 were considered statistically 
significant.
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The study was approved by the institutional review boards of the participating pediatric 
rheumatology centers. Informed consent was obtained from all parents and, as appropriate, 
assent was given by the participants prior to the study procedures.
RESULTS
Patient Profile Raters and Validation Dataset (Steps A and 2)
A total of 2,996 ratings were provided to 503 pediatric rheumatologists and used for Step 2. 
The response-rate of the pediatric rheumatologists to the PP was 54% (274/503; locations: 
30% from the U.S. and Canada; 8% from Australia/Asia, 3% Africa/Middle East, 40% 
South and Central America, and 19% Europe). The majority (69%) of PP raters had over 10 
years of experience in treating cSLE. There were 1860 PP (1860/2996= 62%) that were 
rated by at least 4 raters, hence considered “qualified” for inclusion in Step 3. There were no 
significant differences of distribution of flares between qualified and unqualified PP 
(Fisher’s exact test, p=0.62).
When the Majority-Rule was applied to the “qualified” PP, there were 1318 PP representing 
global flares (510 minor flares, 483 moderate flares and 325 major flares) and 542 
unchanged/improved (29% of 1860 PP). When applying the 67%-Rule to the 1860, only 818 
PP remained available for analysis, among them 484 representing a flare (194 minor flares, 
146 moderate flares and 144 major flares) and 334 PP without cSLE flare. The patient 
characteristics reflected in these PP are summarized in Table 1. PP raters from different 
geographic locations did not differ systematically in the disease course assignment for a 
given PP (North America vs. other countries: ICC = 0.658). Similarly, there was fair to good 
agreement among PP raters with different duration of medical experience (3–5, 6–10, 10–15, 
>15 years) for the interpretation of the disease courses (ICC = 0.656). Additionally, we 
explored other selection criteria (50% Rule, 75% Rule) and found no systematic differences 
with the 50% Rule and 75% resulting in similar adjudication of the PP compared to the 
Majority-Rule and the 67%-Rule, respectively [data not shown].
Performance of Preliminary Algorithms of cSLE global flares (Step C)
The absolute baseline-to-follow-up changes of the parameters considered in the preliminary 
flare algorithms by flare severity and rule are provided in Table 2. Irrespective of the dataset 
(67%-Rule; Majority-Rule), most of the cSLE flare descriptors included in the preliminary 
cSLE flare criteria (ESR, PCR, MD-global, SLEDAI, BILAG) significantly changed 
between the baseline and follow-up visit, by flare severity.
Notably, the accuracy of the SLEDAI-based algorithm was outstanding [AUC= 0.93; 95% 
confidence interval (CI): 0.91– 0.95] as was that of the BILAG-based algorithm [AUC= 
0.93; 95% CI: 0.89– 0.98]. The CART-SLEDAI algorithm had an excellent accuracy for 
identifying patients with global flare of cSLE (any severity) [AUC= 0.89; sensitivity= 
88.8%; specificity= 87.1%]. The same was true for the CART-BILAG criteria [AUC= 0.84; 
sensitivity= 93.9%; specificity= 72.9%]. Comparisons of accuracies in the development data 
set in 2010 (18) and this validation data set are summarized in Table 3.
Brunner et al. Page 7













Flare Thresholds—Figure 2, Panel A and B depict potential thresholds for defining 
minor, moderate and major flares. In this final Consensus Conference, again consensus 
(100%) was reached to use the statistically optimal threshold from logistic models to define 
all threshold scores for the both SLEDAI-based and the BILAG-based algorithms. As shown 
in Figure 3, Panel A and B using these threshold cut-off scores allows for the discrimination 
of minor from moderate or severe flares, all with sensitivities and specificities of ≥ 82%. 
Neither of the CART-based algorithms was suited to discriminate between mild and 
moderate cSLE flares (Figure 3, Panel C and D).
Ranking of the Preliminary cSLE Flare Algorithms (Step D)
Consensus Conference participants achieved consensus that the BILAG-based (92%) and 
SLEDAI-based (100%) flare algorithms have both construct validity for measuring global 
flares of cSLE. There was consensus (100%) to recommend both measures to be collected in 
future cSLE clinical trials and that either one may be chosen as the primary endpoint. 
Consistent with their performance in the validation data set, no consensus was reached 
whether one of these two algorithms was preferable to the other. Consensus was achieved 
that CART-based algorithms are not suited for use in clinical trials, given that these 
algorithms cannot be used to discriminate minor from moderate cSLE flares. The results of 
this study were reviewed by the ACR Criteria Subcommittee and the ACR Quality of Care 
Committee.
DISCUSSION
The need to develop internationally agreed upon criteria for disease flares has become more 
urgent since the introduction of randomized withdrawal trials in pediatric rheumatology, in 
which time to flare or the proportion of patients who experience a flare are used as primary 
efficacy measures (28). We confirm the outstanding accuracy of the previously developed 
preliminary criteria of global flares of cSLE, based on large international datasets used for 
validation. Consensus has been achieved on how to interpret flare scores. The preferred 
cSLE global flare algorithms for use in clinical trials were derived from multinomial logistic 
regression models. These algorithms consider the differential and complementary 
contribution of select cSLE flare descriptors in identifying disease flares in this disease with 
highly variable multi-organ involvement. Despite consensus that CART-based algorithms are 
potentially of value when used in clinical care settings, there was agreement that they should 
not be used in clinical trials.
As for SLE in adulthood, measures of the overall course are especially relevant because not 
all cSLE features improve or worsen in parallel. Current drugs used in cSLE therapy are not 
equally effective in reducing disease activity in the various organ systems. Thus it is 
reasonable to assume that the same holds true for new or emerging drugs for cSLE. In 
clinical trials aimed at reducing cSLE-mediated inflammation in certain organ systems, it 
appears mandatory to ensure that global disease, i.e. disease manifestations in other than the 
target organ systems, is not worsening. The results of this study support that the SLEDAI-
based and the BILAG-based flare scores are both highly suited to provide such information.
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Based on the current evidence about these algorithms they are similarly sensitive, specific 
and accurate. Hence, Consensus Conference experts considered both algorithms equally 
valuable and suitable for use in clinical trials. Different from what is currently used to gauge 
response to therapy in juvenile idiopathic arthritis (29), flare algorithms derived from 
regression models allow for consideration of the differential importance of changes in 
individual cSLE flare descriptors when recognizing cSLE flares. The SLEDAI-based and 
BILAG-based flare scores are reminiscent of the disease activity score (DAS) used in 
rheumatoid arthritis (30). However, the DAS score considers the natural logarithm of the 
ESR and square roots of the number of swollen or tender joints, while the preliminary cSLE 
flare criteria require at most simple arithmetic maneuvers to calculate a cSLE flare score, 
supporting their ease of use (18).
All flare score algorithms consider changes in proteinuria, despite the inclusion of 
proteinuria assessment in the SLEDAI and BILAG scores. This allows for detection of renal 
SLE flares that occur in patients with existing proteinuria and also allows for the 
consideration of increases in proteinuria that would otherwise not be captured given the item 
definition used in the SLEDAI and BILAG, respectively. As reported previously, exclusion 
of changes in proteinuria from the flare algorithms resulted in inferior accuracy in predicting 
cSLE flares (14).
In line with our earlier studies (5, 8) both cSLE flare criteria from CART and multinomial 
logistic regression analysis showed excellent or even outstanding accuracy. Statistically, they 
were superior to algorithms that considered equally weighted percentage changes from a 
statistical point of view in the past.
Given the simplicity of CART-based criteria, they appear particularly suited for clinical 
settings but a potential short-coming of CART-based criteria include so-called ‘over-fitting 
of the mathematical model’ which can make them prone to less favorable statistical 
performance in subsequent validation studies (14). Mild cSLE flares often do not prompt 
clinicians to change therapy, whereas moderate cSLE generally require more intensive anti-
inflammatory therapy. Although CART-based flare algorithms were highly accurate for 
discriminating any kind of global flare when tested in this validation data set, they were 
unable to distinguish minor from moderate cSLE flares. This limitation prompted the 
agreement among the Consensus Conference experts to not recommend CART-based 
algorithms for use as outcome measures in clinical trials.
We chose two approaches to adjudicate the disease course (67%-Rule, Majority-Rule) 
presented in the various PPs, which might have introduced bias. However, both approaches 
yielded comparable results.
The ACR has outlined a series of validation steps necessary before new criteria are to be 
widely used for clinical care or research (12). Among others, one step is to use data from 
clinical trials for developing response criteria. However, clinical trial data from interventions 
that impact cSLE activity are unavailable at present. In our study, the presence of a flare was 
based on the PP raters’ perception of the course of cSLE instead. Given their prospective 
character and the expertise of the PP raters, we consider the quality of our data to be high 
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and the number of PPs per flare severity category yielded robust provisional cSLE flare 
criteria.
We would like to point-out that PP raters from different parts of the world and different 
degrees of experience showed all excellent concordance (inter-rater agreement) in their 
assessment of the cSLE course. This supports the robustness of this validation study. A 
limitation might be that only 54% of those physicians approached to provide PP ratings 
provided feed-back. Nonetheless, responses from 274 pediatric rheumatologists were 
obtained, which is a much larger number than for many similar validation exercises (9–11).
In addition to criteria for global flare and improvement, criteria for changes of cSLE in 
specific organ systems are likely needed. Depending on the proposed effect of a cSLE drug 
candidate, the Cutaneous Lupus Activity and Severity Index (31), pediatric lupus nephritis 
response measures (32) and standardized joint assessments for children (29), have already 
been validated to adequately capture the proposed therapeutic effects. To further provide 
support for the accuracy of the provisional criteria of global flare of cSLE data from clinical 
trials will be needed.
Taken together a methodologically stringent validation process has been employed to 
calculate a flare score that can be used to interpret the course of cSLE over time with respect 
to the degree of worsening that might have occurred. Based on the data available these 
algorithms cannot be used to quantify potential improvement over time.
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B. Patient Profiles considering the BILAG
Gerd Ganser St. Josef Stift Sendenhorst Ganser@St-Josef-Stift.De
Claas Hinze University Hospital Muenster Claas.Hinze@Gmail.Com
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Elzbieta Smolewska Medical University, 
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Enid del Valle San Jorge Children’s Hospital, 
San Juan
Enidjdelvalle@Gmail.Com
Elivette Zambrana HIMAHealth, San Juan Ezambrana@Hotmail.Com
Romania:
Constantin Ailioaie II Paediatric Clinic, Children’s 
Emergency Hospital “St. 
Mary”
Laserail_Mail@Yahoo.Com
Calin Lazar Pediatric Clinic, no.1, 
University of Medicine and 




Ekaterina Alekseeva Scientific Centre of Children’s 
Health,Russian Academy of 
Medical Sciences
Alekatya@Yandex.Ru




Sulaiman Al-Mayouf King Faisal Specialist Hospital 
& Research Center, Riyadh
Mayouf@Kfshrc.Edu.Sa
Abdurhman Asiri Prince Sultan Military Medical 
City (PSMMC)
Asiri1000@Yahoo.Com
Wafaa Sewairi King Fahad National Guard 




Gordana Susic Belgrade Institute of 
Rheumatology, Belgrade
Susic.Gordana@Gmail.Com
Gordana Vijatov-Djuric Institute for Child and Youth 




Elizabeth Ang National University Children’s 
Medical Institute, Singapore
rheum_kids@nuhs.edu.sg
Thaschawee Arkachaisri KK Women’s and Children’s 
Hospital and Duke-NUS 
Medical School
Thaschawee.Arkachaisri@Kkh.Com.Sg
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y Cajal, Madrid
al_boter@yahoo.com
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Isabel Bolt Kinderspital, Universität Zürich Isabel.Bolt@Insel.Ch
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Dieneke Schonenberg-Meinema Emma’s Children Hospital, 




Leonia Dans University of the Philippines-
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Karen Joy Kimseng Chong Hua Hospital and Cebu 




Seza Ozen Hacettepe University, Ankara Sezaozen@Hacettepe.Edu.Tr
United Kingdom:
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Hospital, Liverpool
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• Results of the preliminary validation of criteria of global flare for childhood-
onset SLE are provided.
• Based on the flare scores mild flares, moderate flares and severe flares can be 
defined.
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Figure 1. Flow diagram of the entire process used to develop and validate the approved criteria 
of global flare of cSLE
The steps 1–5 have been summarized in Brunner & Klein-Gitelman: Arthritis Care Res 
(Hoboken). 2010;62(6):811–20; and Brunner & Mina: Arthritis Care & Research. 
2011;63(9):1213–23. The current report commences at step 5 and focuses on steps 6 – 8.
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Figure 2. Potential flare thresholds to define cSLE flare severity. Panel A: SLEDAI-based 
algorithm, Panel B: BILAG-based algorithm
Flare threshold values based on multinominal logistic regression models and distribution-
weighted strategies for each flare category (minor, moderate, major flare) were presented to 
the experts participating in the final concensus conference. There was 100% agreement to 
use threshold values derived from multinomial logistic regression, i.e. thresholds with the 
best statisticial performance in receiver-operating characteristic curve analysis. Each 
threshold had the largest summation of sensitvity and specificity on the ROC curve. Blue 
bars represent threshold scores from multinomial logistic regrssion models and yellow bars 
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depict those derived from distribution-weighted approaches. Red bars indicate the scores 
using each algorithm to assess the 2010 data (14).
 Distribution-weighted
 Logistic
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Figure 3. Flare score interpretation
Flare scores represent the cut-off score on the Receiver Operating Characteristic (ROC) 
curves that provide the best discrimination between adjacent disease states (no flare, minor 
or mild flare, moderate flare, major or severe flare) with cSLE. Sensitivities and specificities 
are shown for the SLEDAI-based algorithm in Panel A, and the BILAG-based algorithm in 
Panel B. As shown in Panel C, the SLEDAI-CART algorithm [Score= 4 if 3 ≤ SLEDAI; 
Score= 3 if 0.7 ≤ PCR and 3 > SLEDAI; Score= 2 if 2 ≤ MD and 0.7 > PCR and 3 > 
SLEDAI; and Score=1 Otherwise] and in Panel D the BILAG-CART algorithm [Score= 4 if 
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2 ≤ BILAG; Score= 3 if 0.7 ≤ PCR and 2 > BILAG; Score= 2 if 2 ≤ MD and 0.7 > PCR and 
2 > BILAG; Score= 1 Otherwise] are only able to distinguish major flares from other cSLE 
disease courses. Thus the other two of the top preliminary flare criteria (SLEDAI-CART, 
BILAG-CART) were unable to discriminate minor from moderate cSLE flare.
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Table 1
Baseline Characteristics of Validation Cohort
Values are % from N, unless stated otherwise Majority Rule (N=1860) 67% Rule (N=818)
Mean age (Years) 15.0 15.1
Gender (% Of Females) 81.7% 82.5 %
Protein-Creatinine Ratio* 0.39
 ≤ 0.2 63.8% 67.5%
 > 0.2 36.2% 32.5%
 > 0.5 14.5% 13.0%
 > 2.0 3.4% 2.7%
Organ Involvement With Active cSLE At Baseline 2.7% 7.0%
 Neuropsychiatric 12.4% 8.67%
 Musculoskeletal 21.7% 22.6%
 Mucocutaneous 15.4% 12.7%
 Hematologic 24.1% 20.5 %
 Renal 1.2% 1.0%
 Cardiopulmonary 2.7% 8.1%
 Constitutional symptoms
*
either from 24 hour urine or random urine sample; (mg protein/mg urine creatinine)
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Table 3
Comparison of the Performance of the Preliminary Flare Algorithm in the Development and Validation 
Dataset
Algorithm details Flare Category
Area under the ROCˆ 
curve
2010 data 2017 data
SLEDAI-based flare score$ Score=0.5 × SLEDAI + 0.45 × PCR
** + 0.5 × MD 
+ 0.02 ESR
Major flare 0.95 0.93
At least moderate 
flare
0.85 0.94
At least minor flare 0.86 0.93
BILAG-based flare score$
Score=0.4 × BILAG + 0.65 × PCR + 0.5 × MD + 0.02 
ESR
Major flare 0.93 0.91
At least moderate 
flare
0.85 0.92
At least minor flare 0.85 0.93
SLEDAI-based CART rule
Score=4 if 3 ≤ SLEDAI;
Score=3 if 0.7 ≤ PCR and 3 > SLEDAI;
Score=2 if 2 ≤ MD and 0.7 > PCR and 3 > SLEDAI;
Score=1 Otherwise.
Major flare 0.85 0.76
At least moderate 
flare
0.80 0.80
At least minor flare 0.84 0. 89
BILAG-based CART rule
Score=4 if 2 ≤ BILAG;
Score=3 if 0.7 ≤ PCR and 2 > BILAG;
Score=2 if 2 ≤ MD and 0.7 > PCR and 2 > BILAG;
Score=1 Otherwise.
Major flare 0.86 0.71
At least moderate 
flare
0.80 0.75
At least minor flare 0.82 0.84
*
Details about algorithm development are provided in Brunner, H. I., Mina, R. “Preliminary criteria for global flares in childhood-onset systemic 
lupus erythematosus.” Arthritis Care Res (Hoboken) 2011, 63(9): 1213–1223.
$
Algorithm considers for the change (baseline – follow-up) of each of the flare descriptors included
†
Values presented represent the area under the ROC curve considering PP with consensus as defined by the 67%-Rule
**
PCR: Urine protein/creatinine ratio from random urine sample
#
MD-global: Physician global assessment of disease measured on a visual analog scale (range: 0–10; 0= inactive disease)
‡
Numeric values larger than or equal to the flare score signify a flare; higher scores are seen with more severe flare.
ˆ
Receiver operating characteristic
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